- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Decision by the Disciplinary Committee regarding Magle Chemoswed Holding AB | 154 | GlobeNewswire | Stockholm, August 17, 2026 - The Disciplinary Committee of Nasdaq Stockholm (the "Exchange") has found that Magle Chemoswed Holding AB (the "Company") has breached the rules of Nasdaq First North... ► Artikel lesen | |
| MAGLE CHEMOSWED Aktie jetzt für 0€ handeln | |||||
| 12.08. | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Second Quarter 2026 | 77 | GlobeNewswire (Europe) | Early signs of stabilisation in a year of transition
Q2 2026 KEY INDICATORS (Apr-Jun)Total revenue amounted to 74.6 MSEK (55.2)EBITDA equalled 1.5 MSEK (-20.6)Operating profit (EBIT) was -13.1 MSEK... ► Artikel lesen | |
| 27.07. | The observation status for Magle Chemoswed Holding AB is updated | 198 | GlobeNewswire | On June 9, 2026, the shares in Magle Chemoswed Holding AB (the "Company") were given observation status with reference to uncertainty in respect of the issuer's financial position.
Today, July... ► Artikel lesen | |
| 27.07. | Magle Chemoswed Holding AB: The board of Magle Chemoswed Holding AB (publ) proposes that the EGM resolves on voluntary delisting of the company's shares from Nasdaq First North Growth Market | 236 | GlobeNewswire (Europe) | The board of directors of Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), has today resolved to propose that an extraordinary general meeting resolves on the delisting of the... ► Artikel lesen | |
| 10.07. | Magle Chemoswed Holding AB: Magle Group Has Resolved On A Restructuring Of Its Outstanding Debt And Capital Structure, Including Debt-for-equity Swap, Issuance Of Super Senior Bonds And Directed Share Issues | 359 | GlobeNewswire (Europe) | As previously announced, Magle Chemoswed Holding AB (publ) ("Magle Group" or the "Company") has for some time been in constructive negotiations with bondholders representing approximately 79 per cent... ► Artikel lesen | |
| 30.06. | Magle Chemoswed Holding AB: Bulletin from the Annual General Meeting in Magle Chemoswed Holding AB (publ) | 197 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), today, on 30 June 2026, held its Annual General Meeting at the Company's premises at Agneslundsvägen 20B in Malmö. The following... ► Artikel lesen | |
| 25.06. | Magle Chemoswed Holding AB: Magle Group announces deferral of interest payment in respect of its bonds, and update to timing of intended financial restructuring | 214 | GlobeNewswire (Europe) | As communicated by Magle Chemoswed Holding AB (publ) ("Magle Group" or the "Company") on 11 June 2026, the Company received a proposal from an ad hoc group of bondholders (the "Ad Hoc Group") in respect... ► Artikel lesen | |
| 09.06. | Magle Chemoswed Holding AB receives observation status | 196 | GlobeNewswire | On June 7, 2026, Magle Chemoswed Holding AB (the "Company") disclosed a press release with an update regarding the Company's financing arrangements.
According to item 6.1.3 (b) (iv) of the Nasdaq... ► Artikel lesen | |
| 07.06. | Magle Chemoswed Holding AB: Magle Chemoswed Holding AB - Update on Financing Arrangements and Ongoing Stakeholder Discussions | 198 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ) ("Magle" or the "Company") provides an update regarding its financing arrangements and ongoing discussions with key stakeholders.
Danske Bank Facility Maturing on 30... ► Artikel lesen | |
| 31.05. | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For First Quarter 2026 | 196 | GlobeNewswire (Europe) | A difficult quarter in a year of necessary change
Q1 2026 KEY INDICATORSTotal revenue amounted to 71.7 MSEK (85.1)EBITDA equalled -6.6 MSEK (12.8)Operating profit (EBIT) was -17.8 MSEK (2.1)Profit after... ► Artikel lesen | |
| 26.05. | Magle Chemoswed Holding AB: Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ) | 295 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), today, on 26 May 2026, held an Extraordinary General Meeting (the "EGM") at the Company's premises at Agneslundsvägen 20B in... ► Artikel lesen | |
| 12.05. | New last trading day for paid subscription shares (BTA) of Magle Chemoswed Holding AB | 275 | GlobeNewswire | At the request of Magle Chemoswed Holding AB, the last trading day in Magle Chemoswed Holding AB's paid subscription shares will be changed from 2026-05-20 to 2026-05-13.
Instrument:
Paid subscription... ► Artikel lesen | |
| 30.04. | Magle Chemoswed Holding AB: Magle Group Announces Outcome of Rights Issue | 276 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 14.04. | Magle Chemoswed Holding AB: Magle Group Publishes Information Document in Connection with Upcoming Rights Issue | 302 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 13.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026 | 213 | Xetra Newsboard | Das Instrument LUR SE0015192075 LUXBRIGHT AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026 The instrument LUR SE0015192075 LUXBRIGHT AB EQUITY is traded ex capital adjustment on 13.04.2026Das... ► Artikel lesen | |
| 10.04. | Magle Chemoswed Holding AB: Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ) | 221 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), today, on 10 April 2026, held an Extraordinary General Meeting (the "EGM") at the Company's premises at Agneslundsvägen 20B in... ► Artikel lesen | |
| 27.03. | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2025 | 253 | GlobeNewswire (Europe) | Magle Group's Q4 report highlights restructuring measures, portfolio clean-up and a focus on improving profitability in a challenging financial environment.
Q4 2025 KEY INDICATORSNet Sales amounted... ► Artikel lesen | |
| 25.03. | Magle Chemoswed Holding AB: Magle Group's Board Of Directors Has Resolved On A Rights Issue Of Approx Sek 40 Million And Agreed A Revised Financing Package | 260 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 18.02. | Magle Chemoswed Holding AB: Magle Group Issues Profit Warning Ahead of Q4 and Full-Year 2025 Results | 237 | GlobeNewswire (Europe) | Magle Group today issues a profit warning in advance of the publication of its Q4 2025 Interim Report and Full-Year 2025 Results, now scheduled for release on March 27, 2026.
This follows the Group's... ► Artikel lesen | |
| 29.01. | Magle Chemoswed Holding AB: Magle Group Announces Strategic Refocus to Strengthen Profitability and Operational Discipline | 314 | GlobeNewswire (Europe) | Magle Group today announces a strategic direction focused on strengthening profitability, operational discipline, and long-term value creation. The Group will prioritise its most established revenue-generating... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 48,040 | -1,17 % | Bayer ist mehr als die Roundup-Wette | Bayer hat an der Börse lange fast nur über ein einziges Thema funktioniert: Glyphosat. Gute Pharmadaten, Agrarwachstum oder Sparprogramme wurden regelmäßig von neuen US-Rechtsrisiken überlagert. Im... ► Artikel lesen | |
| MERCK KGAA | 137,95 | -0,07 % | Bundeskartellamt gibt Übernahme von Bio-Techne durch Merck KGaA (Darmstadt) frei | Das Bundeskartellamt hat heute die geplante Übernahme des US-amerikanischen Biotechnologieunternehmens Bio-Techne, Minneapolis, durch die Merck KGaA aus Darmstadt freigegeben. Das Vorhaben ist auch... ► Artikel lesen | |
| JUPITER NEUROSCIENCES | 6,250 | +0,81 % | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders... ► Artikel lesen | |
| NOVO NORDISK | 39,980 | +0,01 % | Novo Nordisk unter Druck, Eli Lilly greift Europa an, GSK beschleunigt - warum Pharma jetzt breiter denken muss | ||
| ETON PHARMACEUTICALS | 63,35 | -0,19 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DXCM, ORKA, CON, ATAI | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| PFIZER | 24,000 | -0,12 % | Nur ganze 16 bieten im S&P 500 mehr Dividende als die 10J-Staatsanleihen? Platz 1 VICI Properties, Platz 2 Pfizer... | Nur 16 Unternehmen im S&P 500 bieten noch eine Dividende, die höher liegt als die aktuelle Rendite der 10-jähringen Treasuries um 4,7 %. Das ist die kleinste Anzahl seit 2007. Unten im Anhang finden... ► Artikel lesen | |
| MERCK & CO | 130,78 | +0,14 % | Den Krebs im Fokus: Merck & Co., Vidac Pharma und AstraZeneca! | Aktuell gibt es laut der Internationalen Krebsforschungsagentur (IARC) der WHO rund 20,6 Millionen Krebsfälle. Die Zahl der Todesfälle wird auf jährlich etwa 10 Millionen Menschen geschätzt. In den... ► Artikel lesen | |
| ELI LILLY | 1.075,00 | +0,04 % | Warum Eli Lilly 3,8 Milliarden US-Dollar auf Psychedelika setzt - und Emyria plötzlich an einem entscheidenden Engpass sitzt | ||
| BIOHAVEN | 13,850 | 0,00 % | Biohaven Ltd.: Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results | First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed... ► Artikel lesen | |
| SCHOTT PHARMA | 23,050 | +1,32 % | EQS-News: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma treibt Klimaschutz mit aktualisierten wissenschaftsbasierten Klimazielen voran | EQS-News: SCHOTT Pharma AG & Co. KGaA
/ Schlagwort(e): ESG
SCHOTT Pharma treibt Klimaschutz mit aktualisierten wissenschaftsbasierten Klimazielen voran
17.08.2026 / 17:32... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 77,42 | 0,00 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,650 | -0,21 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,110 | -0,06 % | Cathie Woods Biotech-Offensive lenkt den Blick auf datengetriebene Healthcare-Unternehmen - Emyria baut klinische Präsenz aus | ||
| SANOFI | 78,44 | +0,14 % | UBS stuft SANOFI auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Sanofi mit einem Kursziel von 78 Euro auf "Neutral" belassen. Mit Blick auf den Antikörper-Wirkstoff Lunsekimig gegen Asthma... ► Artikel lesen | |
| LB PHARMACEUTICALS | 47,500 | -0,25 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into... ► Artikel lesen |
MAGLE CHEMOSWED HOLDING AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,028 Euro und damit 0,00 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAGLE CHEMOSWED HOLDING AB finden Sie auf Wallstreet Online.